Alpha-1 Antitrypsin Deficiency (AATD) is a genetic disorder in which the vast majority of patients are unidentified or misdiagnosed, and experience significant delays in diagnosis. This is a pertinent and timely clinical issue, as specific therapeutic intervention is available for AATD patients. Also, the treatment landscape is continuing to evolve, with active clinical research and emerging therapies for associated lung and liver disease.


James Stoller, M.D., M.S.

Chairman, Education Institute, Cleveland Clinic
Jean Wall Bennett Professor of Medicine
Samson Global Leadership Academy Endowed Chair
Cleveland Clinic Lerner College of Medicine View Full Bio


Joint Accreditation Logo

In support of improving patient care, this activity has been planned and implemented by University of Kentucky HealthCare CECentral and Mercury Market Development LLC. University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA credit
This live activity is designated for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.



This activity is jointly provided by the University of Kentucky and Mercury Market Development LLC.

Supported by an unrestricted educational grant from Takeda Pharmaceuticals North America, Inc.